2020 年第 4 期 第 15 卷

前蛋白转化酶枯草溶菌素9抑制剂Alirocumab对动脉粥样硬化性心血管疾病影响的研究现状

Research status of the effect of alirocumab on atherosclerotic cardiovascular disease

作者：鲁亦凡顾伟李志忠张京梅

英文作者：Lu Yifan Gu Wei Li Zhizhong Zhang Jingmei

单位：首都医科大学附属北京安贞医院心内科十五病房100029

英文单位：The Fifteenth Ward of Department of Cardiology Beijing Anzhen Hospital Capital Medical University Beijing 100029 China

关键词：动脉粥样硬化性心血管疾病；前蛋白转化酶枯草溶菌素9抑制剂；Alirocumab；低密度脂蛋白胆固醇

英文关键词：Atheroscleroticcardiovasculardisease；Proproteinconvertasesubtilisin/kexintype9inhibitor；Alirocumab；Lowdensitylipoproteincholesterol

• 摘要：

• 【摘要】动脉粥样硬化性心血管疾病（ASCVD）是现在全球范围内造成死亡人数最多的疾病，其发生主要与低密度脂蛋白胆固醇（LDL-C）在动脉内膜的沉积与聚集而导致动脉粥样硬化斑块的形成有关。因此，将LDL-C控制在合理水平是ASCVD防治的重要途径。前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂可以通过抑制其介导的LDL-C受体降解来增加血浆中LDL-C的清除率，从而达到降低LDL-C水平和改善心血管疾病预后的目的。Alirocumab是一种重要的PCSK9抑制剂，也是近年来降脂治疗的研究热点。本文针对Alirocumab的有效性和安全性进行深入探讨，并对其临床研究ODYSSEY试验等进行综述。

• 【Abstract】Atherosclerotic cardiovascular disease(ASCVD) is a leading cause of death around the world. The formation of atherosclerotic plaque is mainly related to the deposition and accumulation of low density lipoprotein cholesterol（LDL-C） in artery intima. Reasonable control of LDL-C plays an important role in the prevention of ASCVD. Proprotein convertase subtilisin/kexin type 9(PCSK9) inhibitor can increase the clearance rate of plasma LDL-C by inhibiting LDL-C receptor degradation, thus reducing LDL-C level and improving the prognosis of cardiovascular damage. Alirocumab, a typical PCSK9 inhibitor, becomes a research hotspot of lipid-lowering therapy in recent years. This article discussed the efficacy and safety of Alirocumab, and reviewed relevant clinical trials, including ODYSSEY trial.